EDINBURGH, Scotland, Dec. 18,
2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer, announced today that the creation of a
new Commercial Development Division, which will be headed by Dr.
Lauren Bor, PhD.
The new division will focus on optimizing production of TCB-008
in anticipation of ACHIEVE data in 2024 as well as the recent IND
clearance for TCB-008 in the US, and preparing a clear regulatory
path for commercialization, as well as the research of new and
developing technologies for future efficiencies in the
manufacturing process. Additionally, TC BioPharm's Commercial
Development Division will explore new opportunities with third
parties to monetize the company's production capabilities using the
GMP licensed facility.
"I have the utmost confidence in Lauren's ability spearhead this
new business unit and continue to represent TC BioPharm as a leader
in Women in STEM," stated Bryan
Kobel, Chief Executive Officer. "The creation of this
division will prepare TCB for successful trial data and regulatory
commercialization filings in the future, a key focus of regulators
in cell therapy, and it will also allow us to avoid costly
supply-chain delays by leveraging our strong manufacturing
capabilities. We expect there to be continued advancement
production and manufacturing of cell therapies, Dr. Bor will be
locking in our process as well as have an eye to these advancements
and bringing our process to the highest grade and best economics
for commercialization at scale. This increase in oversight is also
expected to create a more efficacious product in cell therapy and
make us stronger as we work to pioneer a new and powerful class of
gamma-delta T cell therapies for the treatment of cancer."
Prior to serving as TC BioPharm's Head of Process Development,
Dr. Bor completed a Bsc Hons degree in Immunology from the
University of Glasgow.
She obtained her Ph.D in Immunobiology, titled "The Generation
of MHC Class I Restricted Antigen Specific Regulatory T Cells for
the treatment of Type 1 Diabetes" from Kings
College London in 2014. Dr. Bor then joined the
lab of Professor Waseem Qasim at
University College London as a Post-Doctoral Researcher where she
led the development of closed-system, automated manufacturing
platforms for CAR T cells. Following successful manufacture of CD19
CAR T cells for clinical trials and scale up of gene edited CAR T
cells at UCL. Lauren Joined TC BioPharm in 2019, and her area of
research has been the process development and technology transfer
of TC BioPharm's Unmodified cryopreserved Vγ9Vδ2 T cell
manufacturing process.
"I am excited to lead this new division at TC BioPharm as we
look out to commercializing our manufacturing process and advancing
our ability to scale efficiently in cell therapy manufacturing,"
said, Dr. Bor. "TC BioPharm understands that early-stage biotech
companies have different needs and expectations than that of large
pharmaceutical companies. I believe our new undertaking will allow
us to operate within this niche market to better serve those
specific needs."
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC BioPharm uses
an allogeneic approach in both unmodified and CAR modified
gamma-delta T cells to effectively identify, target and eradicate
both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogeneic
CryoTC technology to provide frozen product to clinics worldwide.
TC BioPharm also maintains a robust pipeline for future indications
in solid tumors as well as a significant IP/patent portfolio in the
use of CARs with gamma-delta T cells and owns our manufacturing
facility to maintain cost and product quality controls.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-formation-of-commercial-development-division-led-by-industry-veteran-dr-lauren-bor-phd-302017987.html
SOURCE TC BioPharm